Merus has been granted a patent for novel PD-1 binding domains with higher affinity for human PD-1 and potent blocking capabilities. The invention includes binding moieties for treating diseases like cancer by targeting the suppressed immune system. Nucleic acids encoding these domains are also covered in the patent. GlobalData’s report on Merus gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Merus, Personalized cancer vaccines was a key innovation area identified from patents. Merus's grant share as of May 2024 was 25%. Grant share is based on the ratio of number of grants to total number of patents.
Novel pd-1 binding domain with high affinity for treatment
A recently granted patent (Publication Number: US11993654B2) discloses an anti-human PD-1 binding domain that includes a heavy chain variable region with specific amino acid sequences. The domain comprises various combinations of heavy chain CDR1, CDR2, and CDR3 sequences, as detailed in the patent claims. Additionally, the binding domain may include a light chain variable region with specific amino acid sequences, further enhancing its anti-PD-1 binding capabilities.
Furthermore, the patent describes a binding moiety that incorporates the anti-PD-1 binding domain, potentially leading to the development of monospecific binding moieties. These binding moieties could have significant applications in the field of pharmaceutical compositions. The patent also mentions the formulation of a pharmaceutical composition containing the anti-human PD-1 binding domain and a pharmaceutically acceptable carrier, indicating the potential for therapeutic use of this innovative technology in the treatment of various conditions related to PD-1.
To know more about GlobalData’s detailed insights on Merus, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
